Back to top
more

Shire plc (SHPG)

(Delayed Data from NSDQ)

$179.20 USD

179.20
NA

0.00 (0.00%)

Updated Jan 4, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1

by Zacks Equity Research

Merrimack (MACK) reports wider-than-expected loss in the first quarter.

    Shire (SHPG) Q1 Earnings Beat, Rare Disease Franchise Strong

    by Zacks Equity Research

    Shire (SHPG) reports better-than-expected first-quarter earnings and records strong growth in immunology franchise and newly launched products.

      Shire (SHPG) Turns Down Takeda's Third Buyout Proposition

      by Zacks Equity Research

      Shire (SHPG) declines Takeda Pharmaceutical's third acquisition offer in a cash-stock deal.

        Taye Baldinazzo headshot

        Why Is Allergan (AGN) Stock Falling Today?

        by Taye Baldinazzo

        Allergan (AGN) shares have fallen 5.8% on the day, while Shire plc (SHPG) is up 3.4% so far. These fluctuations come in light of a $50 billion dollar acquisition deal for Shire that is now taking a competitive turn.

          Sanofi to Divest European Generic Unit, Streamline Business

          by Zacks Equity Research

          Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.

            Shire Sells Oncology Unit Ahead of Takeda's Potential Offer

            by Zacks Equity Research

            Shire (SHPG) sells its oncology segment to France-based Servier for $2.4 billion. Takeda remains on track to make a potential offer for Shire.

              Shire (SHPG) is in Overbought Territory: What's Next?

              by Zacks Equity Research

              Shire plc (SHPG) has moved higher as of late, but there could definitely be trouble on the horizon for this company

                Shire's Stock Continues to Rise as Takeda Sets Eyes On it

                by Zacks Equity Research

                Takeda expressed its intention to take over Shire (SHPG) to boost its geographic presence and product portfolio.

                  Shire (SHPG) Soars: Stock Adds 12.2% in Session

                  by Zacks Equity Research

                  Shire (SHPG) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.

                    Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4

                    by Zacks Equity Research

                    Merrimack (MACK) reports narrower-than-expected loss in the fourth quarter due to lower operating expenses.

                      Shire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong

                      by Zacks Equity Research

                      Shire (SHPG) reported better-than-expected fourth-quarter earnings and also registered strong growth in immunology franchise and newly launched products.

                        Shire (SHPG) to Report Q4 Earnings: What's in the Cards?

                        by Zacks Equity Research

                        Shire (SHPG) will report its Q4 results on Feb 14, 2018.

                          Allergan (AGN) Q4 Earnings Beat on Increase in Botox Sales

                          by Zacks Equity Research

                          Allergan (AGN) beats expectations for both earnings and revenues in Q4. A phase III study evaluating Allergan's migraine candidate, ubrogepant meets its co-primary endpoints.

                            Shire Gets FDA Nod for Cinryze Tech Transfer to New Site

                            by Zacks Equity Research

                            Shire (SHPG) receives an FDA approval for transferring the product manufacturing technology of its hereditary angioedema drug, Cinryze, to its manufacturing site in Vienna, Austria.

                              Nektar Boasts Strong Pipeline, Competition Remains a Woe

                              by Zacks Equity Research

                              Nektar (NKTR) impresses with a strong pipeline of early and late-stage candidates. The company makes a significant progress with its lead candidate, Onzeald, for advanced breast cancer in adults.

                                Allergan's (AGN) Sales Guidance for 2018 Lower Than Expected

                                by Zacks Equity Research

                                Allergan (AGN) announces weaker-than-expected sales outlook for 2018. A generic version of Restasis is expected to be launched in Q2.

                                  Allergan to Cut Jobs Amid Loss of Exclusivity for Key Drugs

                                  by Zacks Equity Research

                                  Allergan (AGN) is laying off over 1,000 employees as part of a cost-cutting and restructuring program as it faces potential loss of exclusivity for some of its key products in 2018.

                                    Protalix (PLX) Fabry Disease Candidate Gets Orphan Status

                                    by Zacks Equity Research

                                    Protalix BioTherapeutics's (PLX) pipeline candidate, PRX-102, gets orphan drug status in Europe which is being developed as a treatment for Fabry disease.

                                      Shire's New Formulation of Oncaspar Gets Approval in Europe

                                      by Zacks Equity Research

                                      Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar receives approval from the European Commission.

                                        Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease

                                        by Zacks Equity Research

                                        Ultragenyx (RARE) clinches an FDA approval for rhGUS, a treatment option of mucopolysaccharidosis VII. The company assures the drug to be available in the United States by the month-end.

                                          Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval

                                          by Zacks Equity Research

                                          Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.

                                            Shire Gets Positive CHMP Opinion for Hemophilia A Drug

                                            by Zacks Equity Research

                                            Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

                                              Allergan (AGN) Tops Q3 Earnings Estimates, Tweaks 2017 View

                                              by Zacks Equity Research

                                              Allergan (AGN) beat expectations for earnings while delivering in-line revenues in Q3. While the company slightly lowered its sales guidance, it raised the upper end of the earnings guidance.

                                                Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong

                                                by Zacks Equity Research

                                                Shire (SHPG) reported better-than-expected third-quarter earnings and also registered strong growth in immunology franchise. Shares were up in response.

                                                  Allergan (AGN) to Report Q3 Earnings: What's in the Cards?

                                                  by Zacks Equity Research

                                                  While Allergan's (AGN) Q3 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products will hurt sales.